Logo
Logo

About Fondaparinux Sodium API

Product
  • Therapeutic CategoryCardiovascular

  • CAS Number

    114870-03-0

  • API Technology

    Synthetic

  • Dose Form

    Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, Canada DMF, EUDMF, China DMF

Mechanism of Action

The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development.

Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affect fibrinolytic activity or bleeding time.

Indication

ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for:

  • Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery.
  • Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin.

Related APIs

Amlodipine Besylate

Cardiovascular

arrow

Apixaban

Cardiovascular

arrow

Bempedoic Acid

Cardiovascular

arrow

Clopidogrel Bisulfate (Form 1)

Cardiovascular

arrow

Clopidogrel Bisulfate (Form 2)

Cardiovascular

arrow

Dabigatran Etexilate Mesylate

Cardiovascular

arrow

Doxazosin Mesylate

Cardiovascular

arrow

Ezetimibe

Cardiovascular

arrow

Fondaparinux Sodium

Cardiovascular

arrow

Lacidipine

Cardiovascular

arrow

Losartan Potassium

Cardiovascular

arrow

Mavacamten

Cardiovascular

arrow

Metoprolol Succinate

Cardiovascular

arrow

Ramipril

Cardiovascular

arrow

Rivaroxaban

Cardiovascular

arrow

Tafamidis Free Acid

Cardiovascular

arrow

Tafamidis Meglumine

Cardiovascular

arrow

Ticagrelor

Cardiovascular

arrow

Treprostinil

Cardiovascular

arrow

Treprostinil Olamine

Cardiovascular

arrow

Valsartan

Cardiovascular

arrow

Atorvastatin Calcium (Amorphous And Form P)

Cardiovascular

arrow

Sacubitril-Valsartan

Cardiovascular

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.